BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of comm ...

BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conc ...

"Our strategic decision to transition to a distributor model in international geographies is proving to be highly successful," said Annie Mitchell, CFO of Allbirds. "Over the past 18 months, we have partnered with world- class distributors and extended our brand reach with a profitable operating model. With the signing of these three new agreements, we look forward to bringing the Allbirds brand to additional countries throughout Eurasia." Beosport Aleksandar Ivanovic, Director of Beosport, stated, "We are ...

SHENZHEN, July 09, 2025 (GLOBE NEWSWIRE) -- MingZhu Logistics Holdings Limited (“MingZhu” or the “Company”) (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced that on July 7, 2025, it executed a non-binding memorandum of understanding (“MOU”) with ENEXTREND.VN COMPANY LIMITED (“Enextrend”), a Vietnam registered company which owns the emerging cross-border e-commerce platform – Muamau Mall. The strategic partners plan to leverage their respective expert ...

Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva’s commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Invent ...

About Duolingo PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Duolingo, Inc. (Nasdaq: DUOL), the world's leading mobile learning platform, will announce its results for the second quarter ending June 30, 2025, following the close of the U.S. market on Wednesday, August 6, 2025. The Company will host a video webcast at 5:30 p.m. ET on that day. The live video webcast will be accessible to the public through Duolingo's Investor Relations website at https://investors.duolingo.com. A replay of the event will be ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Key Takeaways Navitas Semiconductor (NVTS) has delivered a standout performance in 2025, with its stock skyrocketing 246% over the past three months, far outpacing the broader Electronics - Semiconductors industry, the Computer and Technology sector and benchmark indices like the S&P 500. The rally has also outpaced the broader PHLX Semiconductor Index's (SOX) 58.3% growth. While revenue growth remains modest, investor enthusiasm is fueled by Navitas' expanding customer pipeline, new design wins and growing ...

The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated These results confirm findings from the previously published RELIEF phase 3 trial, which also demonstrated a statistically significant reduction in fibromyalgia pain FDA target PDUFA date for TNX-102 SL is August 15, 2025 and, if approved, would be the first new drug fo ...

PHILADELPHIA, July 9, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it has launched an investigation into the fairness of the recently announced buyout of TaskUs, Inc. (Nasdaq: TASK) shareholders to determine whether the proposed buyout price of $16.50 per share undervalues the company's shares.Click here for additional information about this investigation: https://kaskelalaw.com/case/taskus-buyout/On May 9, 2025, TaskUs announced that it had agreed to be acquired by the company's co-founders and Blac ...